Equities Analysts Offer Predictions for RCUS Q1 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Equities researchers at Leerink Partnrs issued their Q1 2026 earnings estimates for Arcus Biosciences in a note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings per share of ($0.55) for the quarter. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Leerink Partnrs also issued estimates for Arcus Biosciences’ Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($0.11) EPS and FY2029 earnings at $0.79 EPS.

RCUS has been the topic of several other research reports. HC Wainwright upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $18.00 to $24.00 in a report on Wednesday. Morgan Stanley decreased their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Arcus Biosciences in a research report on Thursday, November 7th. Finally, Bank of America dropped their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, February 19th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $30.25.

Arcus Biosciences Stock Down 0.8 %

Shares of NYSE:RCUS opened at $10.16 on Thursday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm’s 50-day simple moving average is $13.57 and its 200-day simple moving average is $15.46. Arcus Biosciences has a fifty-two week low of $9.92 and a fifty-two week high of $20.31. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -3.22 and a beta of 0.84.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $36.00 million during the quarter, compared to analysts’ expectations of $29.38 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. R Squared Ltd acquired a new stake in shares of Arcus Biosciences in the fourth quarter worth $26,000. Point72 Hong Kong Ltd purchased a new stake in Arcus Biosciences during the 3rd quarter worth $47,000. Lazard Asset Management LLC increased its holdings in Arcus Biosciences by 3,321.3% in the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock valued at $93,000 after purchasing an additional 6,078 shares in the last quarter. US Bancorp DE raised its position in Arcus Biosciences by 2,432.0% in the fourth quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after purchasing an additional 6,615 shares during the period. Finally, Quest Partners LLC lifted its stake in shares of Arcus Biosciences by 40,904.3% during the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after purchasing an additional 9,408 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Arcus Biosciences

In other news, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the sale, the chief financial officer now owns 60,138 shares in the company, valued at approximately $902,070. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 12.30% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.